FDA advisers to review ALS drug funded by Ice Bucket Challenge
Stephen Scelsa, MD, discusses the potential of new drug, Amylyx developed to slow the development of ALS. He said, “It's possible, that a Phase 3 trial could reveal the drug doesn't work as expected, even though the Phase 2 trial showed there was an apparent benefit. I think this will probably pan out and show an effect, but as a scientist, I’d like to see Phase 3 data.”